New Insights into Alzheimer's Treatment: Targeting GRK2 with Compound 10

ETH Zurich's Ursula Quitterer and her team have unveiled promising findings with their experimental treatment, referred to as Compound 10, which could have significant implications for Alzheimer's disease progression. Preliminary tests in mice indicate that this chemical may effectively slow nerve cell death associated with dementia, resulting in increased lifespan for treated subjects.

The genesis of this research dates back nearly two decades, originating from brain tissue samples taken from patients at Ain Shams University Hospital in Cairo, provided by a colleague of Quitterer's. These samples, obtained during tumor surgeries, included tissues from both dementia-afflicted individuals and those without the condition.

At the heart of Quitterer's investigation is the enzyme GRK2, known for its vital regulatory role across various human cells. GRK2 assists in managing cellular responses to signals and stress, being particularly active in key organs such as the brain and heart. The latest results, published in Cell Reports Medicine, suggest that GRK2's activity is closely tied to the mechanisms underlying dementia.

The research revealed that within the brain tissue of dementia patients, there exists a concerning accumulation of an inactive form of GRK2. An analogous pattern was observed in a mouse model for Alzheimer’s disease. These inactive forms of GRK2 were also found to aggregate within brain cells, forming clumps that attach to mitochondria. Quitterer explains that these aggregates impede mitochondrial function, significantly reducing their energy output and consequently escalating cellular stress.

Interestingly, the study also demonstrated that inactive GRK2 appears to stimulate the production of amyloid beta, a protein fragment recognized as a key contributor to Alzheimer's pathology. This creates a harmful feedback loop: elevated amyloid beta induces further stress in nerve cells, which in turn promotes the accumulation of more inactive GRK2 and aggregates, accelerating dementia progression.

To disrupt this harmful cycle, Quitterer and her team developed several chemical compounds, with Compound 10 emerging as particularly effective. This compound prevents GRK2 from forming aggregates, enhancing mitochondrial function and reducing amyloid beta levels in treated cells. As a result, nerve cells maintained a healthier state, leading to improved survival rates.

Beyond its potential application for Alzheimer's, Compound 10 also seemed to enhance heart function and influence signs of aging in experimental mice, such as reducing grey hair development. These comprehensive benefits suggest that targeting GRK2 aggregation might extend beyond neurological conditions, possibly influencing other age-related processes.

While the findings are promising, it's important to note that they are still preclinical. Compound 10 has yet to reach human trials. The research team has filed for a patent and concluded the basic research phase, paving the way for future developments.

The slow progress in Alzheimer's research, as Quitterer points out, is partly due to the disease's complexity and the need for studies involving older animals—about one and a half years or older. Each experiment often spans multiple years of research to yield meaningful conclusions.

At this juncture, Quitterer and ETH Zurich are actively pursuing partnerships with pharmaceutical companies to advance Compound 10 into subsequent stages of drug development. There’s an urgent need for new treatment strategies, as current medications only offer modest delays in disease progression without halting its course.

Identifying GRK2 as a new target protein, combined with Compound 10's different mechanism of action, could provide a complementary approach to existing Alzheimer’s therapies. The hope is that in the future, this compound could enhance the quality of life for patients dealing with this challenging condition.

Materials provided by ETH Zurich. Note: Content may be edited for style and length.

This Strange New Magnetism Could Change How Computers Work

Scientists Decode a 12,000-Year-Old Mystery Hidden in Ancient Spear Points

Switzerland’s Glaciers Lost More Than 5% of Their Ice in Just One Year

Scientists Tested This Tropical Fruit for Diabetes – and Found an Unexpected Blood Pressure Effect

Stay informed with ScienceDaily's free email newsletter, updated daily and weekly. Or view our many newsfeeds in your RSS reader:

Keep up to date with the latest news from ScienceDaily via social networks:

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?